EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Lanthanum carbonate treatment of hyperphosphatemia in end-stage renal disease






Journal of Pharmacy Technology 22(2): 99-104

Lanthanum carbonate treatment of hyperphosphatemia in end-stage renal disease

Objective: To review the literature on the safety and efficacy of lanthanum carbonate for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD).Data Sources: Primary literature was obtained through a PubMed search (1966-September 2005) using the key terms Fosrenol and lanthanum carbonate.


Accession: 012255440

DOI: 10.1177/875512250602200206



Related references

Guo, H.; Zhang, X.; Tang, S.; Zhang, S., 2014: Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate. To assess the effect and safety of lanthanum carbonate (LC) for hypophosphatemia in patients with end-stage renal disease (ESRD). According to the collaborative review group search strategy, we searched MEDLINE (1996 to 2012.12); EBCO (1996 to 201...

Brennan, A.; Akehurst, R.; Davis, S.; Sakai, H.; Abbott, V., 2007: The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. To assess the cost-effectiveness of lanthanum carbonate (LC) as a second-line therapy for hyperphosphatemia in end-stage renal disease (ESRD) patients not achieving target phosphorus levels. A cohort of ESRD patients not adequately maintained on c...

Park, H.; Rascati, K.L.; Keith, M.S.; Hodgkins, P.; Smyth, M.; Goldsmith, D.; Akehurst, R., 2012: Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. To assess the cost-effectiveness of lanthanum carbonate (LC) versus sevelamer hydrochloride (SH) as a treatment for hyperphosphatemia in end-stage renal disease (ESRD) patients. A Markov model was developed to estimate health outcomes; quality-adj...

Persy, V.P.; Behets, G.J.; D.B.oe, M.E.; D'Haese, P.C., 2009: Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate. Elevated serum phosphate levels as a consequence of chronic kidney disease (CKD) contribute to the increased cardiovascular risk observed in dialysis patients. Protein restriction and dialysis fail to adequately prevent hyperphosphatemia, and in g...

Shigematsu, T.; Ohya, M.; Negi, S.; Masumoto, A.R.; Nakashima, Y.M.; Iwatani, Y.; Moribata, M.K.; Yamanaka, S.; Tatsuta, K.; Mima, T., 2016: Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients. In end-stage renal disease patients, various abnormalities of bone mineral metabolism adversely affect mortality. Hyperphosphatemia is known to adversely affect mortality and quality of life in chronic kidney disease patients and has been shown to...

Yang, W.C.ang; Chiang, S.S.an; Chen, J.B., 2003: Efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in Chinese chronic renal failure patients. Journal of the American Society of Nephrology 14(Abstracts Issue): 204A, November

Vegter, S.; Tolley, K.; Keith, M.S.; Postma, M.J., 2011: Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Hyperphosphatemia is a common and harmful condition in patients with chronic kidney disease (CKD). We determined the cost-effectiveness of the noncalcium-based phosphate binder lanthanum carbonate (LC) as second-line treatment of hyperphosphatemia...

Scaria, P.Thomas.; Gangadhar, R.; Pisharody, R., 2010: Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease. The tolerability and efficacy of lanthanum carbonate has not been studied in the Indian population. This study was, therefore, undertaken to compare the efficacy and tolerability of lanthanum carbonate with calcium acetate in patients with stage 4...

Chiang, S.S.; Chen, J.B.; Yang, W.C., 2005: Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. High serum phosphorus levels are a common problem in patients receiving long-term dialysis treatment. Lanthanum carbonate (Fosrenol) is a new non-aluminum, non-calcium phosphate binder developed for the treatment of hyperphosphatemia in patients w...

Freemont, A.J.; Hoyland, J.A.; Denton, J., 2005: The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Renal osteodystrophy is a common complication of end-stage renal disease (ESRD) and is a major cause of morbidity in patients with ESRD. High serum levels of phosphorus, calcium and parathyroid hormone are associated with the development of this d...